Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 111 entries
View as:

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

Phase: N/A Priority: Normal
NCT ID: NCT00062816 Org: User:
Start: 06/30/03 End: 01/31/04 Due: 01/31/05

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Phase: N/A Priority: Normal
NCT ID: NCT02160899 Org: User:
Start: 06/30/14 End: 11/30/15 Due: 11/30/16

Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD)

Phase: N/A Priority: Normal
NCT ID: NCT06150716 Org: User:
Start: 04/10/24 End: 06/30/28 Due: 06/30/29

Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01918865 Org: User:
Start: 08/31/13 End: 02/28/15 Due: 02/28/16

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547

Phase: N/A Priority: Normal
NCT ID: NCT04934891 Org: User:
Start: 03/24/21 End: 09/14/22 Due: 09/14/23

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04398485 Org: User:
Start: 01/20/21 End: 09/30/24 Due: 09/30/25

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Phase: N/A Priority: Normal
NCT ID: NCT04768972 Org: User:
Start: 06/14/21 End: 03/31/28 Due: 03/31/29

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

Phase: N/A Priority: Normal
NCT ID: NCT01234038 Org: User:
Start: 11/30/10 End: 01/31/13 Due: 01/31/14

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00330330 Org: User:
Start: 02/28/03 End: 08/31/06 Due: 08/31/07

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT00063414 Org: User:
Start: 11/20/02 End: 03/24/05 Due: 03/24/06

Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).

Phase: N/A Priority: Normal
NCT ID: NCT03728634 Org: User:
Start: 12/21/18 End: 02/20/20 Due: 02/20/21

REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT06914609 Org: User:
Start: 05/31/25 End: 04/30/30 Due: 04/30/31

Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

Phase: N/A Priority: Normal
NCT ID: NCT04059406 Org: User:
Start: 09/24/20 End: 03/28/23 Due: 03/28/24

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Phase: N/A Priority: Normal
NCT ID: NCT05667493 Org: User:
Start: 11/30/22 End: 08/31/29 Due: 08/31/30

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

Phase: N/A Priority: Normal
NCT ID: NCT02476019 Org: User:
Start: 06/30/15 End: 09/30/16 Due: 09/30/17

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Phase: N/A Priority: Normal
NCT ID: NCT05392114 Org: User:
Start: 07/13/22 End: 03/31/27 Due: 03/31/28

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Phase: N/A Priority: Normal
NCT ID: NCT02175004 Org: User:
Start: 06/26/14 End: 01/07/21 Due: 01/07/22

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03582462 Org: User:
Start: 07/09/18 End: 04/26/19 Due: 04/26/20

Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

Phase: N/A Priority: Normal
NCT ID: NCT06360237 Org: User:
Start: - End: - Due: -

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

Phase: N/A Priority: Normal
NCT ID: NCT04568434 Org: User:
Start: 11/18/20 End: 10/17/23 Due: 10/17/24

A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

Phase: N/A Priority: Normal
NCT ID: NCT00002156 Org: User:
Start: - End: - Due: -

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02211209 Org: User:
Start: 12/31/14 End: 03/28/17 Due: 03/28/18

Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00836225 Org: User:
Start: 01/31/09 End: 01/31/12 Due: 01/31/13

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Phase: N/A Priority: Normal
NCT ID: NCT05071300 Org: User:
Start: 01/04/22 End: 08/31/29 Due: 08/31/30

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Phase: N/A Priority: Normal
NCT ID: NCT04136171 Org: User:
Start: 03/13/20 End: 08/31/26 Due: 08/31/27